仿形(计算机编程)
医学
癌症
肿瘤科
病理
内科学
计算机科学
操作系统
作者
Raghav Sundar,Drolaiz Hw Liu,Gordon G.A. Hutchins,Hayley Slaney,Arnaldo N. S. Silva,Jan Oosting,Jeremy D. Hayden,Lindsay C. Hewitt,Cedric Chuan Young Ng,Amrita Nargund Mangalvedhekar,Sarah Ng,Iain Tan,Patrick Tan,Heike I. Grabsch
出处
期刊:Gut
[BMJ]
日期:2020-11-23
卷期号:70 (10): 1823-1832
被引量:68
标识
DOI:10.1136/gutjnl-2020-320805
摘要
Objective Endoscopic mucosal biopsies of primary gastric cancers (GCs) are used to guide diagnosis, biomarker testing and treatment. Spatial intratumoural heterogeneity (ITH) may influence biopsy-derived information. We aimed to study ITH of primary GCs and matched lymph node metastasis (LN met ). Design GC resection samples were annotated to identify primary tumour superficial (PT sup ), primary tumour deep (PT deep ) and LN met subregions. For each subregion, we determined (1) transcriptomic profiles (NanoString ‘PanCancer Progression Panel’, 770 genes); (2) next-generation sequencing (NGS, 225 gastrointestinal cancer-related genes); (3) DNA copy number profiles by multiplex ligation-dependent probe amplification (MLPA, 16 genes); and (4) histomorphological phenotypes. Results NanoString profiling of 64 GCs revealed no differences between PT sup1 and PT sup2 , while 43% of genes were differentially expressed between PT sup versus PT deep and 38% in PT sup versus LN met . Only 16% of genes were differently expressed between PT deep and LN met . Several genes with therapeutic potential (eg IGF1 , PIK3CD and TGFB1 ) were overexpressed in LN met and PT deep compared with PT sup . NGS data revealed orthogonal support of NanoString results with 40% mutations present in PT deep and/or LN met , but not in PT sup . Conversely, only 6% of mutations were present in PT sup and were absent in PT deep and LN met . MLPA demonstrated significant ITH between subregions and progressive genomic changes from PT sup to PT deep /LN met . Conclusion In GC, regional lymph node metastases are likely to originate from deeper subregions of the primary tumour. Future clinical trials of novel targeted therapies must consider assessment of deeper subregions of the primary tumour and/or metastases as several therapeutically relevant genes are only mutated, overexpressed or amplified in these regions.
科研通智能强力驱动
Strongly Powered by AbleSci AI